MedWarn.org
  • Alerts
  • Drugs
    • ADHD Medications
    • Allergy Treatments
    • Antidepressants
    • Antipsychotics
    • Antibiotics
    • Antiseizure
    • Arthritis
    • Cancer Treatments
    • Cardiovascular
    • Diabetes Treatments
    • Dietary Supplements/Weight Loss
    • Erectile Dysfunction
    • Gastrointestinal
    • Hormone Therapy
    • Oral Contraception
    • Pain Relief
    • Respiratory
    • Skin Conditions
    • Sleep
  • Vaccines/Biologics
    • Blood Products
    • Genetic Testing
    • Tissues
    • Vaccines
  • Devices
    • 3D Printed
    • Autoinjectors
    • Brain Devices
    • Breast Implants
    • Cardiac Devices
    • Contraceptive Devices
    • Cyber Security
    • Home Health Devices
    • Hip Implants
    • Infusion Pumps
    • Respiratory Systems
    • Stents
    • Surgical Devices
    • Transvaginal Mesh
  • Tobacco
  • Resources
    • Product Safety and the FDA
    • Product Recalls
    • Product Liability Lawsuits
    • Questions For A Lawyer
    • Get Help
  • About Us

Alerts, Recalls, and Legal Headlines

Sign-up to receive recall notices, medical news, and litigation updates.

SIGN-UP

FDA Approves Alprolix to Treat Hemophilia B With Fewer Injections

3/31/2014

0 Comments

 
The FDA has approved Alprolix as a new treatment for Hemolilia B.  Alprolix (Coagulation Factor IX (Recombinant), Fc Fusion Protein) is manufactured by Biogen Idec, Inc. and is the first Hemophilia B treatment designed to last longer in circulation and require fewer injections.

Hemophilia B is an inherited sex-linked, blood-clotting disorder, which primarily affects males, and is caused by defects in the Factor IX gene. Hemophilia B affects about 3,300 people in the United States. People with Hemophilia B can experience repeated episodes of potentially serious bleeding, mainly into the joints, which over time can destroy the joints.

Alprolix  was approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures, and prevent or reduce the frequency of bleeding episodes (prophylaxis). Alprolix consists of the Factor IX molecule linked to a protein fragment, Fc, which is found in antibodies and makes the product last longer in circulation.

[1] FDA News Release, "FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B," March 28, 2014.
 


0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    September 2013
    July 2013
    June 2013
    May 2013
    March 2013
    January 2013
    July 2012
    June 2012
    March 2012
    February 2012
    August 2011
    December 2010
    August 2010
    February 2009
    July 2008

    RSS Feed

    Categories

    All
    3D Printing
    3D Printing
    Acid Reducers
    Acne Treatments
    ADHD
    Allergies
    Antibiotics
    Antidepressants
    Anti-Epilepsy
    Antipsychotics
    Antiviral
    Arthritis
    Aspirin
    Asthma
    Autism
    Birth Control
    Birth Defects
    Blood Products
    Bone
    Brain
    Cancer
    COPD
    Cyber Crime
    Diabetes
    Dietary Supplements
    Dna-testing
    E-cigarettes
    Electronic Health Records
    Eliquis
    Epilepsy
    FDA/Approvals
    FDA Recalls
    FDA/Recalls
    FDA Warnings
    FDA Warnings
    Hearing-devices
    Hearing Loss
    Heart
    Hemophilia
    Hip Implants
    Hormone
    HPV
    Infants
    Infusion Pump
    Invokana
    Legal News
    Migraines
    Mirena
    Monitors
    Multiple Sclerosis
    Pain Relief
    Research
    Resuscitation
    Risperdal
    Sleep
    Stents
    Stroke
    Surgical Device
    Surgical Device
    Topamax
    Transvaginal Mesh
    Vaccine
    Weight Control
    Weight Control

    RSS Feed



    120x600
Powered by Create your own unique website with customizable templates.
Photos used under Creative Commons from Official U.S. Navy Imagery, madaise, outcast104, archibald jude, Vee-vee